Mar 14, 2024
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Mar 05, 2024
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
Feb 28, 2024
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Jan 29, 2024
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
Jan 09, 2024
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
Jan 03, 2024
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Jan 03, 2024
Keros Therapeutics Announces Proposed Public Offering of Common Stock
Jan 03, 2024
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity